World J Gastroenterol. 2008 June 28; 14(24): 3792-3797.
Published online 2008 June 28. doi: 10.3748/wjg.14.3792.
Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract
Ammar Natalwala, Robert Spychal and Chris Tselepis.
Ammar Natalwala, The Medical School, University of Birmingham, Birmingham B15 2TT, United Kingdom
Robert Spychal, Sandwell and West Birmingham Hopsitals NHS Trust, Birmingham B15 2TT, United Kingdom
Chris Tselepis, CRUK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, United Kingdom
Author contributions: Natalwala A, Spychal R and Tselepis C contributed to the writing, editing and reviewing of the manuscript.
Correspondence to: Dr. Chris Tselepis, CRUK Institute for Cancer Studies, University of Birmingham, Vincent Drive, Birmingham B15 2TH, United Kingdom. c.tselepis@bham.ac.uk
Telephone: +44-121-4142972
Fax: +44-121-6272384
Received February 5, 2008; Revised April 25, 2008; Accepted May 2, 2008;
Abstract
Epithelial-mesenchymal transition (EMT) is a highly conserved process that has been well characterised in embryogenesis. Studies have shown that the aberrant activation of EMT in adult epithelia can promote tumour metastasis by repressing cell adhesion molecules, including epithelial (E)-cadherin. Reduced intracellular adhesion may allow tumour cells to disseminate and spread throughout the body. A number of transcription proteins of the Snail superfamily have been implicated in EMT. These proteins have been shown to be over-expressed in advanced gastrointestinal (GI) tumours including oesophageal adenocarcinomas, colorectal carcinomas, gastric and pancreatic cancers, with a concomitant reduction in the expression of E-cadherin. Regulators of EMT may provide novel clinical targets to detect GI cancers early, so that cancers previously associated with a poor prognosis such as pancreatic cancer can be diagnosed before they become inoperable. Furthermore, pharmacological therapies designed to inhibit these proteins will aim to prevent local and distant tumour invasion.
Keywords: Epithelial-mesenchymal transition, Transcription proteins, E-cadherin, Gastrointestinal cancer
INTRODUCTION
Epithelial-mesenchymal transition (EMT) is a well-characterised embryological process that has been considered to play a vital role in tumour progression[15]. EMT has been shown to occur during gastrulation, as well as during the development of the neural crest, heart and the musculoskeletal system[6]. In the process of EMT, epithelial cells undergo a phenotypic switch to form mesenchymal cells that are similar in appearance to fibroblasts[23]. The change in cell type results in the loss of polarity and also the loss of tight intracellular adhesions maintained by epithelial cells via adherens junctions[13]. This is thought to allow dynamic cellular migration and increase embryogenic diversity[5]. However, in vitro evidence has outlined a role for the aberrant induction of EMT in adult epithelia during tumour metastasis[67]. In primary tumours, the induction of EMT can lead to structural changes involving cell adhesion molecules, and in particular epithelial-cadherin (E-cadherin)[810]. E-cadherin is a transmembrane glycoprotein that is localised in the adherens junction typically found in epithelial cells, and plays an important role in maintaining the structural integrity of epithelial sheets[11]. The loss of E-cadherin expression has been reported in several GI cancers including advanced colorectal carcinomas, oesophageal adenocarcinomas, gastric and pancreatic cancers[1215]. Interestingly, experiments used to silence the expression of E-cadherin not only showed a morphological shift from an epithelial to a fibroblastoid phenotype, characteristic of EMT, but also a concomitant increase in invasive cell behaviour[16]. The loss of E-cadherin has been considered to augment cellular dissemination and tumour metastasis.
The mechanisms by which E-cadherin has been shown to be inactivated include gene mutations, promoter hypermethylation, chromatin remodelling, post-translational modification and transcriptional repression[1719]. The major proteins implicated in the transcriptional repression of E-cadherin include the zinc finger proteins Snai1 (Snail) and Snai2 (Slug), δEF (ZEB-1), Smad interacting protein 1 (SIP1) or ZEB-2, and a basic helix-loop-helix (bHLH) protein called Twist[2022]. Snail was initially described in Drosophila melanogaster and was shown to be essential for dorsal-ventral patterning and mesoderm formation[23]. Knockout studies revealed that mice lacking the Snail gene died at gastrulation due to defective EMT[24]. Snail was found to down-regulate epithelial markers such as claudins, occludens, desmoplakin and cytokeratins, in addition to E-cadherin, and up-regulate mesenchymal markers including fibronectin and vitronectin during EMT[2526]. Its homologue, Slug was discovered in developing chick embryos, and was found to be abundantly expressed in cells undergoing EMT in the primitive streak, neural crest and other mesenchymal tissue[26]. Over expression of Slug in mice induced the formation of mesenchymal tumours that were mainly leukaemias and sarcomas[27]. It was discovered that both Snail and Slug are able to bind directly to E-box motifs (CANNTG) on target gene promoters, and in particular the CDH1 gene in order to down-regulate E-cadherin expression[20]. The zinc finger proteins ZEB-1 and SIP1 were also shown to be able to repress E-cadherin by binding to similar DNA sites as Snail on the E-cadherin promoter region[28]. Furthermore, microarray analysis revealed Twist as another strong candidate for the acquisition of invasive properties of tumour cells, although its mechanism of action is less clear[22].
ROLE OF E-CADHERIN REPRESSORS IN CANCERS OF THE UPPER GASTROINTESTINAL TRACT
Cancers of the upper GI tract, including oral, oesophageal and gastric tumours, are associated with significant mortality worldwide[2931]. Tumours arising in the oral cavity are predominantly squamous cell carcinomas (SCC) in origin and have a tendency to spread rapidly[32]. Oral cancer accounts for around 197 000 deaths each year, throughout the world[33]. E-cadherin expression in normal oral mucosa, compared to pre-cancerous oral lesions and primary oral SCC has been shown to be sequentially lower in each of these stages, respectively[34]. Moreover, Snail-mediated repression of E-cadherin has been confirmed in oral SCC cell lines[35]. Further analysis of primary and recurrent oral SCC, showed that the over-expression of Snail in the primary oral SCC lead to ZEB-1 and SIP1 up-regulation with a concomitant loss of E-cadherin[36]. This expression profile, now matching that of the recurrent oral SCC, may suggest that Snail is able to regulate the function of other E-cadherin repressors such as ZEB-1 and SIP1 in oral SCC.
Repression of E-cadherin has also been reported for advanced human oesophageal cancers[37]. These tumours are known to be particularly aggressive and have a 5-year survival rate of around 8% in the United Kingdom[38]. Oesophageal cancer is histologically divided into squamous cell carcinomas and adenocarcinomas. Oesophageal SCC commonly arises in the upper third of the oesophagus and its predominant aetiological factors include alcohol and nicotine abuse[39]. Analysis of tissue samples from patients with oesophageal SCC suggests that Snail is associated with repressed E-cadherin expression in these primary tumours[40]. In addition, Slug has been shown to be over-expressed in primary oesophageal SCC, correlating with depth of tumour invasion, lymph node metastasis and poorer clinical outcome[41]. Similarly, evaluation of Twist in oesophageal SCC revealed significantly higher Twist expression relative to non-neoplastic tissue[42].
Conversely, oesophageal adenocarcinomas arise in the lower third of the oesophagus[39]. The strongest known risk factor for the development of oesophageal adenocarcinoma is the presence of Barrett’s metaplasia[43]. This is a pre-malignant state that is characterised by the replacement of native squamous oesophageal epithelium by columnar cells, and is considered to occur secondary to prolonged reflux of gastric content in the lower part of the oesophagus[44]. A recent study by Jethwa et al has reported an over-expression of nuclear Slug in oesophageal adenocarcinoma relative to both normal squamous and Barrett’s metaplasia specimens[45]. Interestingly, no such association was observed for both Snail and Twist[4546].
Gastric carcinomas also form part of the upper GI cancers, and although the incidence of these tumours seems to be declining, they are still responsible for around 700 000 deaths per annum, worldwide[47]. According to Lauren’s classification, gastric cancer can be subdivided into two morphologically distinct groups; diffuse and intestinal gastric cancers[48]. The aetiology of gastric cancer has been mainly linked to E-cadherin mutations, promoter hypermethylation and H pylori infection, but there is scarce literature on the role of E-cadherin repressors in these tumours[4950]. Snail-regulated repression of E-cadherin has been reported for diffuse gastric cancer[25], and over-expression of Slug has been shown in both diffuse and intestinal gastric carcinoma[51]. Previous work has also shown that in diffuse gastric carcinomas, raised Twist expression correlates with reduced E-cadherin levels, whereas in intestinal gastric cancer, SIP1 is mainly associated with reduced expression of E-cadherin[25]. Interestingly, a strong correlation between neuronal-cadherin (N-cadherin) and Twist expression has been reported in diffuse-type gastric carcinoma[25]. The up-regulation of N-cadherin has been associated with an invasive tumour phenotype and is considered to over-ride the function of E-cadherin[52]. Therefore, it is suggested that Twist may be implicated in mediating a switch from E-cadherin to the N-cadherin, in order to increase tumour cell motility[25]. A more recent study has confirmed this by using human gastric carcinoma cell lines to show that the suppression of Twist leads to a loss of cellular migration as well as N-cadherin expression[53].
COLORECTAL CANCER PROGRESSION
Colorectal cancer (CRC) is the third most common malignancy worldwide[54]. Its pathogenesis is characterised by clinical and histopathological changes known as the adenoma-carcinoma sequence, where normal colonic epithelium becomes hyper-proliferative and forms adenomatous polyps that progress to malignant disease[55]. The adenoma-carcinoma sequence is considered to occur as a result of sequential genetic changes involving defined oncogenes and tumour suppressor genes, as proposed by Fearon and Vogelstein in 1990[56]. Several studies have reported mutations of the tumour suppressor adenomatous polyposis coli (APC) gene in CRC[5759]. These mutations are amongst the earliest genetic events found in the majority (up to 80%) of sporadic cases of CRC[6061]. The main tumour suppressor function of APC has been shown to be in its ability to mediate the proteosomal degradation of intracellular β-catenin, a key member of the Wnt signalling cascade[62]. Physiologically, Wnt factors are able to induce the stabilization of cytosolic β-catenin, which then associates with T cell factor/lymphoid enhancer factor-1 (TCF) proteins in the nucleus to initiate the transcription of Wnt target genes[6163]. These include genes such as c-myc, cyclin D1, Ephrin B2 and matrilysin[63]. In CRC, mutations of both APC and β-catenin (in 10% of cases) cause deregulation of intracellular β-catenin levels which leads to the nuclear accumulation of β-catenin[62]. This causes aberrant and constitutive expression of Wnt target genes, and thus the development of CRC[63]. Interestingly, β-catenin can also interact with the cytoplasmic domain of E-cadherin, providing a link to the actin cytoskeleton via its binding to α-catenin[64]. However, it is unclear whether the loss of this interaction with β-catenin, in more aggressive forms of CRC where E-cadherin is down-regulated, promotes TCF-dependent transcription[65].
Several mechanisms of E-cadherin repression have been reported in CRC, including gene mutations and promoter hypermethylation. However, transcriptional repression of E-cadherin and associated up-regulation of Snail is also considered to play a role in the progression of CRC[6668]. Analysis of Snail in human CRC has shown that 78% of the tumour samples examined over-expressed this protein[68]. Slug expression has been shown to be positive in 37% of cases of primary CRC, which correlated significantly with metastatic spread of the cancer[69]. Evidence for ZEB-1, SIP1 and Twist-mediated repression of E-cadherin has not yet been established in CRC[70].
OTHER SOLID TUMOURS OF THE GASTROINTESTINAL SYSTEM
Pancreatic cancer confers possibly the worst prognosis of the GI cancers, since it presents very late[7172]. Evidence suggests that both Snail and Slug are over-expressed in pancreatic tumours[72]. A recent study explored Twist expression in invasive ductal carcinoma (IDC) of the pancreas and its associated pre-malignant lesion intraductal papillary mucinous neoplasia (IPMN). Although it was limited by sample size, Twist expression was found to be significantly higher in IDC compared to matched non-tumourous and IPMN samples[73]. SIP1 expression has also been shown to be raised in pancreatic tumours[74].
Studies have also reported the over-expression of Snail in Hepatocellular carcinomas (HCC)[7576]. Twist expression has also been shown to be raised in HCC, which correlates with the metastatic potential of this type of tumour[77]. Miyoshi et al outlined the role of SIP1 in HCC by showing that transfection of SIP1 into HCC cell lines induced cellular dedifferentiation as well as E-cadherin repression. Vimentin and fibronection, along with various matrix metalloproteinases (MMPs), were also up-regulated, and it was hypothesised that MMP up-regulation augments SIP1-induced HCC progression[78].
CONCLUSION
EMT is a context dependent process that is considered to be involved in the progression of GI tumours[57]. Snail and associated repressors of E-cadherin have been implicated in EMT, and the evidence for their role in GI cancer is summarised in Figure 1. Transcriptional repressors of E-cadherin may be useful therapeutic targets for the prevention of local invasion and distant metastasis in GI malignancies. Inhibition of these proteins may also, for the first time, allow early detection of GI cancers associated with a fatal prognosis such as pancreatic cancer to enable early intervention and avoid the situation where this type of cancer becomes inoperable. The same principle can also be applied to other pre-malignant lesions such as Barrett’s metaplasia to improve the management of oesophageal adenocarcinomas. However, it is important to consider that these transcriptional repressors of E-cadherin, or EMT regulators, also have other cellular functions. Both Snail and Twist have been associated with anti-apoptotic functions and Snail has also been implicated in cell adhesion and migration[7980]. Furthermore, some evidence suggests that the expression of E-cadherin is higher in metastatic foci, such as in CRC, thus the reverse process of EMT, or mesenchymal-epithelial transition (MET), may be required in the formation of distant metastases[8]. Therefore, the grade and location of different GI cancers will also need to be considered before commencing any pharmacological treatment targeting regulators of EMT.
Figure 1
Figure 1
Figure 1
Evidence for the role of EMT regulators in gastrointestinal cancer.
Future studies should also consider the various signalling molecules that activate EMT, including the Epidermal growth factor (EGF) family members, Fibroblastic growth factors (FGF), Insulin-like growth factors (IGF), bone morphogenic proteins (BMP) and Wnt factors[79]. It is necessary to explore the interactions between these molecules, their signalling pathways, and the Snail super-family of proteins in GI tumours. This may allude to novel combined treatment regimes to improve clinical outcome. Whilst it is clear that Snail and associated regulators of EMT are implicated in GI carcinogenesis, the role of EMT in cancer is further complicated by the fact that a number of novel EMT regulators have been identified, including molecules such as MMP-3, Met, Goosecoid, Kaiso, TGF-β, FOXC2, GSK3β, Smad-3, Pez and ILK[4]. Additional research is required to support the growing literature regarding the process of EMT, in order gain full insight into its role in GI cancer progression.
Footnotes
Peer reviewer: Francesco Feo, Professor, Dipartimento di Scienze Biomediche, Sezione di Patologia Sperimentale e Oncologia, Università di Sassari, Via P, Manzella 4, Sassari 07100, Italy
S- Editor Zhong XY L- Editor Lalor PF E- Editor Ma WH
References
1.
Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 2005;233:706-720.
2.
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-142.
3.
Shook D, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev. 2003;120:1351-1383.
4.
Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973-981.
5.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
6.
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548-558.
7.
Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Hofler H. Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs. 2007;185:204-212.
8.
Ikeguchi M, Makino M, Kaibara N. Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol. 2001;77:201-207.
9.
Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5:806-811.
10.
Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198:11-26.
11.
Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest. 2003;112:1776-1784.
12.
Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, Doki Y, Matsui S, Tsukita S, Kikkawa N, Monden M. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol. 1999;111:29-37.
13.
Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett’s esophagus and esophageal adenocarcinomas. Mod Pathol. 1998;11:805-813.
14.
Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W, Sugimura T, Hirohashi S. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA. 1994;91:1858-1862.
15.
Lowy AM, Knight J, Groden J. Restoration of E-cadherin/beta-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery. 2002;132:141-148.
16.
Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene. 1995;11:475-484.
17.
Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res. 2001;61:489-492.
18.
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402-405.
19.
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333-339.
20.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.
21.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84-89.
22.
Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 2004;14:R719-R721.
23.
Boulay JL, Dennefeld C, Alberga A. The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers. Nature. 1987;330:395-398.
24.
Carver EA, Jiang R, Lan Y, Oram KF, Gridley T. The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol. 2001;21:8184-8188.
25.
Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol. 2002;161:1881-1891.
26.
Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3:155-166.
27.
Perez-Mancera PA, Gonzalez-Herrero I, Maclean K, Turner AM, Yip MY, Sanchez-Martin M, Garcia JL, Robledo C, Flores T, Gutierrez-Adan A. SLUG (SNAI2) overexpression in embryonic development. Cytogenet Genome Res. 2006;114:24-29.
28.
Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7:1267-1278.
29.
Zhong LP, Li J, Zhang CP, Zhu HG, Sun J, Zhang ZY. Expression of E-cadherin in cervical lymph nodes from primary oral squamous cell carcinoma patients. Arch Oral Biol. 2007;52:740-747.
30.
Jian WG, Darnton SJ, Jenner K, Billingham LJ, Matthews HR. Expression of E-cadherin in oesophageal carcinomas from the UK and China: disparities in prognostic significance. J Clin Pathol. 1997;50:640-644.
31.
Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC, Yang JM. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol. 2002;8:987-993.
32.
Pereira MC, Oliveira DT, Landman G, Kowalski LP. Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc. 2007;73:339-344.
33.
Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett. 1998;102-103:227-234.
34.
Hung KF, Chang CS, Liu CJ, Lui MT, Cheng CY, Kao SY. Differential expression of E-cadherin in metastatic lesions comparing to primary oral squamous cell carcinoma. J Oral Pathol Med. 2006;35:589-594.
35.
Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R, Nagayama M. Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 2001;37:65-71.
36.
Takkunen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I. Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. J Histochem Cytochem. 2006;54:1263-1275.
37.
Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki Y, Iihara K, Matsui S, Iwazawa T, Nagafuchi A. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res. 1994;54:291-296.
38.
Office for National Statistics Cancer Statistics registra-tions: Registrations of cancer diagnosed in 2002, England Series MB1 no.31. 2003, National Statistics: London. .
39.
Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?. Semin Radiat Oncol. 2007;17:38-44.
40.
Natsugoe S, Uchikado Y, Okumura H, Matsumoto M, Setoyama T, Tamotsu K, Kita Y, Sakamoto A, Owaki T, Ishigami S. Snail plays a key role in E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep. 2007;17:517-523.
41.
Uchikado Y, Natsugoe S, Okumura H, Setoyama T, Matsumoto M, Ishigami S, Aikou T. Slug Expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11:1174-1180.
42.
Yuen HF, Chan YP, Wong ML, Kwok WK, Chan KK, Lee PY, Srivastava G, Law SY, Wong YC, Wang X. Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol. 2007;60:510-514.
43.
Dias Pereira A, Suspiro A, Chaves P. Cancer risk in Barrett’s oesophagus. Eur J Gastroenterol Hepatol. 2007;19:915-918.
44.
Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett’s metaplasia. Lancet. 2000;356:2079-2085.
45.
Jethwa P, Naqvi M, Hardy RG, Hotchin NA, Roberts S, Spychal R, Tselepis C. Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol. 2008;14:1044-1052.
46.
Rosivatz E, Becker KF, Kremmer E, Schott C, Blechschmidt K, Hofler H, Sarbia M. Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch. 2006;448:277-287.
47.
Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633-649.
48.
Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006;20:651-674.
49.
Chan AO. E-cadherin in gastric cancer. World J Gastroenterol. 2006;12:199-203.
50.
Liu YC, Shen CY, Wu HS, Chan DC, Chen CJ, Yu JC, Yu CP, Harn HJ, Shyu RY, Shih YL. Helicobacter pylori infection in relation to E-cadherin gene promoter polymorphism and hypermethylation in sporadic gastric carcinomas. World J Gastroenterol. 2005;11:5174-5179.
51.
Castro Alves C, Rosivatz E, Schott C, Hollweck R, Becker I, Sarbia M, Carneiro F, Becker KF. Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol. 2007;211:507-515.
52.
Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155-163.
53.
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun. 2007;358:925-930.
54.
Early DS, Fontana L, Davidson NO. Translational approaches to addressing complex genetic pathways in colorectal cancer. Transl Res. 2008;151:10-16.
55.
Lee S, Bang S, Song K, Lee I. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol Rep. 2006;16:747-754.
56.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
57.
Scott RJ, van der Luijt R, Spycher M, Mary JL, Muller A, Hoppeler T, Haner M, Muller H, Martinoli S, Brazzola PL. Novel germline APC gene mutation in a large familial adenomatous polyposis kindred displaying variable phenotypes. Gut. 1995;36:731-736.
58.
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130-1134.
59.
Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 2002;38:867-871.
60.
Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359:235-237.
61.
Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut. 2007;56:417-425.
62.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787-1790.
63.
Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans. 2005;33:672-675.
64.
Hulsken J, Birchmeier W, Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol. 1994;127:2061-2069.
65.
Kuphal F, Behrens J. E-cadherin modulates Wnt-dependent transcription in colorectal cancer cells but does not alter Wnt-independent gene expression in fibroblasts. Exp Cell Res. 2006;312:457-467.
66.
Efstathiou JA, Liu D, Wheeler JM, Kim HC, Beck NE, Ilyas M, Karayiannakis AJ, Mortensen NJ, Kmiot W, Playford RJ. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proc Natl Acad Sci USA. 1999;96:2316-2321.
67.
Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut. 2001;48:367-371.
68.
Roy HK, Smyrk TC, Koetsier J, Victor TA, Wali RK. The transcriptional repressor SNAIL is overexpressed in human colon cancer. Dig Dis Sci. 2005;50:42-46.
69.
Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer. 2006;94:1816-1822.
70.
Rosivatz E, Becker I, Bamba M, Schott C, Diebold J, Mayr D, Hofler H, Becker KF. Neoexpression of N-cadherin in E-cadherin positive colon cancers. Int J Cancer. 2004;111:711-719.
71.
Koliopanos A, Avgerinos C, Farfaras A, Manes C, Dervenis C. Radical resection of pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008;7:11-18.
72.
Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13:4769-4776.
73.
Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M. Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer. 2007;120:1634-1640.
74.
Imamichi Y, Konig A, Gress T, Menke A. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 2007;26:2381-2385.
75.
Jiao W, Miyazaki K, Kitajima Y. Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer. 2002;86:98-101.
76.
Sugimachi K, Tanaka S, Kameyama T, Taguchi K, Aishima S, Shimada M, Sugimachi K, Tsuneyoshi M. Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin Cancer Res. 2003;9:2657-2664.
77.
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12:5369-5376.
78.
Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, Miyazaki K. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer. 2004;90:1265-1273.
79.
De Craene B, van Roy F, Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal. 2005;17:535-547.
80.
Castanon I, Baylies MK. A Twist in fate: evolutionary comparison of Twist structure and function. Gene. 2002;287:11-22.